Skip to main content

MindMed to Participate in September Investor Conferences

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  216.51
+3.47 (1.63%)
AAPL  263.73
+11.44 (4.53%)
AMD  240.87
+7.79 (3.34%)
BAC  52.01
+0.73 (1.41%)
GOOG  257.27
+3.48 (1.37%)
META  732.61
+15.70 (2.19%)
MSFT  516.29
+2.71 (0.53%)
NVDA  183.09
-0.13 (-0.07%)
ORCL  276.29
-15.02 (-5.16%)
TSLA  447.17
+7.86 (1.79%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.